Ofei Kelvin
Mercer University College of Pharmacy, Atlanta, Georgia.
Int J Pharm Compd. 2022 Jul-Aug;26(4):298-301.
Prior to the COVID-19 pandemic, hospitals were already experiencing shortages of key injectable drugs. Unprecedented demand due to large numbers of critically ill patients with COVID-19 contributed to these shortages, especially analgesics, sedatives, and paralytics. Advocacy efforts are successfully creating changes that may improve the current situation. The United States Drug Enforcement Administration tried to combat the shortage situation by increasing annual production quotas of controlled substances necessary for COVID-19 care. This situation was discussed by the United States Drug Enforcement Administration in a press-release dated April 7, 2020. In addition to this, the U.S. Food and Drug Administration has provided guidance to compounding pharmacies, allowing for increased flexibility in the compounding and distribution of drug products. The website for the new guidances can be found within the resources provided in this article.
在新冠疫情大流行之前，医院就已经面临关键注射药物短缺的问题。新冠疫情导致大量危重症患者，前所未有的需求加剧了这些短缺，尤其是镇痛药、镇静剂和麻痹剂。宣传努力正在成功带来可能改善当前状况的变革。美国药物管制局试图通过提高新冠疫情护理所需受控物质的年度生产配额来应对短缺局面。美国药物管制局在2020年4月7日的一份新闻稿中讨论了这一情况。除此之外，美国食品药品监督管理局已向配制药房提供指导，允许在药品配制和分发方面增加灵活性。新指导方针的网站可在本文提供的资源中找到。
